A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Developing strategies for managing coronary artery calcification (CAC) in patients with CKD is an important clinical challenge.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Using a two-by-two factorial design, the researchers randomly assigned patients to an MgO group or a control group, and to an AST-120 group or a control group.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The primary outcome was percentage change in CAC score.

What Was Measured

PubMed files the paper under topics including Carbon, Comorbidity, Coronary Artery Disease, Disease Progression, Hospitals, University, Magnesium Oxide and Oxides.

Author keywords: chronic kidney disease, coronary artery calcification, oral carbon adsorbent and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.